Author Manuscript Published OnlineFirst on May 30, 2013 ; DOI: 10.1158/0008-5472. HMGA2 is an architectural transcription factor predominantly expressed in the mesenchyme prior to its differentiation and a regulator of mesenchymal proliferation and differentiation (1, 2) . Because of its endogenous expression pattern, HMGA2 is not detected in normal adult tissues (3), but is misexpressed and disrupted in several mesenchymal benign tumors, most predominantly lipomas (1) . In mice, the Hmga2 null reveals a pygmy phenotype due to the decreased number of mesenchymal cells (3) .
Despite its exquisite and specific expression pattern in the mesenchyme during normal development and its causal role in benign mesenchymal tumorigenesis, there have also been a number of intriguing observations with regards to HMGA2 in malignant epithelial tumors over the past decades.
Interestingly, high HMGA2 expression is correlated to late stage of Dukes' classification in patients with colon cancer (4) and associated with the high histologic grade of invasive ductal type of breast cancer (5) . Misexpression of HMGA2 occurred in parallel with reduced survival rates of patients with breast cancer (6) , colorectal cancer (CRC) (7) , lung cancer (8) and tumor recurrence in oral carcinoma (9) . Author Manuscript Published OnlineFirst on May 30, 2013 ; DOI: 10.1158/0008-5472. behavior. During this transition, mesenchymal cells acquire a morphology appropriate for migration in an extracellular environment and settlement in areas that are involved in organ formation. This important concept is also required during tumor progression and several signaling pathways have been uncovered that are common to EMT in both development and tumor progression (10) . At the invasive front of the tumor, neoplastic cells are found that differ morphologically from other cells in the bulk of the tumor. The invasive front is defined as the onecell thick layer of the primary tumor juxtaposing, and small clusters of cancer cells that have advanced into the host stroma. These tumor cells are incohesive, lack polarity and are dedifferentiated, acquiring a mesenchymal phenotype by the process of EMT (10) . The dedifferentiation of epithelial cells to fibroblastoid, migratory, and more malignant cells also reveal a profoundly altered, mesenchymal gene expression program (11) . It is these mesenchymal-like capabilities of the cells that are said to be necessary for metastasis (10) .
The TGFβ signaling pathway is a major inducer of the EMT during tumor development. In humans, the TGFβ superfamily represents a diverse set of growth factors (12) . The TGFβ cytokines signal by bringing together two pairs of receptor serine/threonine kinases, the type I and type II receptors. On binding these ligands, active type II receptor contacts and phosphorylates the type I receptor (13) which leads to the activation of the canonical Smad pathway.
Smad2 and Smad3, which are known as the receptor-associated Smads (R-Smads), are then phosphorylated by the type I receptor and released to propagate the signal with Smad4 (12) .
In the present study, in order to analyze the complexity of the process of metastasis, we have identified the architectural transcription factor, HMGA2, as being essential for tumor progression, EMT and metastasis in vitro and in vivo.
Furthermore, we demonstrate for the first time that the molecular mechanism of HMGA2 in tumor pathogeneisis is mediated through the activation of the TGFβ signaling pathway in epithelial carcinomas.
Materials and Methods
Cell culture and Invasion Assay. into fresh growth medium containing the G418 sulfate (1mg/ml) and maintained for a week to select stable transfected cells. Matrigel invasion assays were performed as described (14) . Specific shRNAs of Hmga2 were designed as 5'-GGTTAACAGTACCCAATGA-3', 5'-TGGGCTTAATCAGTCACTA-3' and 5'-CACAACAAGTCGTTCAGAA-3' and integrated into a SMARTvector 2.0 lentiviral shRNA (Thermo Scientific Dharmacon, Lafayette, CO, USA). 4T1 mouse breast cancer cells were transduced with the Lentiviral Hmga2-shRNA particles and Non-targeting control-shRNA (NTC-shRNA) particles in the presence of Polybrene (4μg/ml). Eighteen hours post-transduction, these cells were passaged into fresh growth medium containing puromycin (2 μg/ml) and maintained for a week so as to select stable transduced cells.
Immunocytochemistry.
For immunocytochemistry, 10 5 cells were seeded onto CC2-coated chamber slides (Nalge Nunc, Naperville, IL) the day before staining. antibodies were used at 1:500 dilution. The fluorescence was observed under an appropriately equipped Nikon microscope.
Immunohistochemistry and Western blotting.
Paraffin-embedded murine and human samples were sectioned at 4 μm, and stained with polyclonal anti-HMGA2 antibody (3) and monoclonal anti-β-catenin Laboratories, San Francisco, CA). At least 3 sections from each tumor were stained for each antibody study performed. Tissues from Hmga2 null mice were used as negative controls for the anti-Hmga2 antibody. Western blotting was performed as described (9) . Ten micrograms of total protein was run per lane and antibodies were used as described above.
Gene expression analysis.
Total RNA was isolated from tissues and cells using RNeasy Mini kit (Qiagen, Gene Expression Assay (Applied Biosystems) in an ABI Prism 7300HT Sequence Detection System (PE Biosystems, Foster City, CA). The reverse transcription and PCR reactions were performed using TaqMan Reverse Transcriptase Reagents (Applied Biosystems). The relative expression data was calculated by the comparative C T method as described elsewhere (15) .
Mice.
All mice were housed and handled according to the Institutional Animal Care and Use Committee guidelines. Hmga2 specific knockout mice have been described were performed by Student's t-test. The analysis of tumor free percentage was performed by log-rank test. P < 0.05 was considered significant.
Results

HMGA2 Directly Induces EMT and Invasiveness in Epithelial Tumor Cells.
Our initial experiments to understand the function of HMGA2 in epithelial tumorigenesis examined the expression of HMGA2 in a number of human cancer cell lines. The selected cell lines were confirmed to exhibit anchorage independent growth characteristics as previously defined (18) and interestingly, while the expression levels of HMGA1a and HMGA1b remained unchanged, the level of HMGA2 expression was found to be directly proportional to the in vitro anchorage independent growth characteristics of the colon cancer cell lines ( Finally, the HMGA2-transfected SW480 and MCF-7 clones exhibited invasion in the matrigel assay (Fig. 1E) and closely matched the behaviour of the control breast cancer cell line MDA-MB231, which is highly invasive. These results suggest that ectopic HMGA2 expression is sufficient as a "driver" for multiple cancer cell types to undergo the epithelial to mesenchymal transition, which leads to an increase in the invasive behaviour of these cells. 
HMGA2 Is Expressed in Tumor Cells Located at The Invasive Front of The Primary Tumor and in Secondary Metastatic Lesions.
The direct relevance of the mechanistic studies to human tumors was investigated. In colorectal tumors expression of HMGA2 was relatively absent in non-neoplastic (8.5 ± 3.6) and early adenomas (3.6 ± 2.2)( Table 1, Fig. 2 ). In contrast, the carcinomas of increasing severity (Dukes' A through D) showed a progressively increased proportion of HMGA2 positive neoplastic cells (Table 1 , since these tumors are mostly of a dedifferentiated phenotype (17, 21) , but also contain well differentiated areas (22) (Supplementary Fig. 1 ). Additionally, HMGA2 staining can clearly be seen in the metastatic lesion with increased β-catenin staining and loss of E-cadherin (Fig. 2) . Also, the proliferation index (PI) for colonic epithelial cells significantly increased in adenomas as compared to non-neoplastic tissue, while at the same time the fraction of HMGA2 positive cells decreased ( Table 1 Importantly, the mesenchymal-like cells at the invasive front, which exhibited the strongest nuclear HMGA2 accumulation, also demonstrated nuclear relocalization of β-catenin and loss of membrane E-cadherin expression (Fig. 2) .
HMGA2 Activates the TGFβRII and Enhances TGFβ Signaling Pathway.
In order to define the molecular mechanism of HMGA2 related EMT, we decided to investigate the possible relationship between the HMGA2 and TGFβ signalling pathway which is well established to play a role in the EMT (20) and invasion (23) . Consistent with the expression of HMGA2 and its bona fide downstream target gene, Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) (24, 25) , the TGFβRII was highly expressed in MCF7-HMGA2 and MDA-MB231 cells compared to MCF7-Mock cells (Fig. 3A, B) . TGFβ type I receptor (TGFβRI) expression level was unchanged (data not shown). Depletion of HMGA2, on HMGA2 siRNA-treated MDA-MB231 cells down regulated TGFβRII mRNA expression (Fig. 3C) and protein (Fig. 3D) . 
Next, the activation of the TGFβRII by HMGA2 was examined through the phosphorylation status of Smad3. Whereas Smad3 is typically localized in the cytoplasm, activation of the TGFβ pathway causes Smad3 to be phosphorylated and migrate to the nucleus (26) . Although Smad3 expression levels were unchanged in MCF7 or MCF7-HMGA2 cells even after TGFβ1 was added (Fig.   3E ), in the MCF7-HMGA2 cells, the levels of phospho-Smad3 increased as compared to the MCF7-Mock cells with a dramatic enhancement observed in phospho-Smad3 expression levels in the presence of exogenous ligand, TGFβ1.
Just as importantly, Smad3 is observed exclusively in the cytoplasm of MCF7-Mock cells but in the MCF7-HMGA2 cells, expression is most prominent in the nucleus (Fig. 3F) . Taken together, these results suggest that HMGA2 increases the susceptibility to the TGFβ ligand through the activation of TGFβRII and strongly suggests that HMGA2 is upstream of the TGFβ  pathway.
In order to elucidate the direct relevance of the in vitro mechanistic studies, human breast and colorectal cancer tissues were investigated. In breast cancer tumors, a coincident expression pattern was observed for HMGA2 and TGFβRII (Fig. 4 upper, left two lines) . Dukes' C/D CRC, the most severe grade of tumors (17) with a prominent invasive front were also analyzed for the expression of HMGA2 and TGFβRII. Expression was coincident for the two proteins within the cells of CRC tumor tissue at the invasive front (Fig. 4 lower, left two lanes) , but not in the well-differentiated area of the tumor (Fig. 4 middle, left two lanes) .
IGF2BP2 was also strongly expressed at the invasive front of human advanced (Fig. 4 upper, right two lines) and severe grade of human CRC tumors (Fig. 4 lower, right two lines) , but not in the well-differentiated area of CRC tumors (Fig. 4 middle, right lines) . In conclusion, the expression of the TGFβ type II receptor was coincident with HMGA2 and IGF2BP2, which is expressed in the cells that undergo the EMT at the invasive front.
HMGA2 and TGFβRII Expression and Loss of Hmga2 in the MMTV-Wnt1
Transgenic Mouse Breast Cancer Model.
In the MMTV-Wnt1 transgenic mouse model, the expression of Wnt1 induces hyperplasia of breast at two weeks of age and by one year, 90% develop mammary adenocarcinomas (16, 27) . Therefore, the MMTV-Wnt1 transgenic mouse was used as an animal model of epithelial tumors. Interestingly, Hmga2 was expressed in the hyperplastic mammary glands and mammary adenocarcinomas of the Wnt1 transgenic mice (Fig. 5A) (Fig. 5B, upper) . Interestingly, the TGFβRII and and IGF2BP2 expression were observed at the same invasive front on the Hmga2 +/+ genotypic background (Fig. 5B upper) . In addition, the loss of E- (Fig. 5B upper) and relocalization of β-catenin ( Supplementary Fig. 4) were also detected at the same invasive front of Wnt1-mediated tumors on the Hmga2 +/+ genetic background.
Having obtained the encouraging result that Hmga2 was expressed in the MMTV-Wnt1 tumors, the next step was to determine if this correlative result could be extended. Therefore, to examine the in vivo effect of Hmga2 on the initiation and progression of Wnt1-mediated tumorigenesis, the Hmga2 mutation (Fig. 5C) . Interestingly, although Wnt1-mediated tumor formation typically results in a heterogeneous glandular structures with frequent blood-or secretion-filled cysts (27) , no obvious glandular and cystic structures were observed on the
Hmga2
-/-genotypic background (Fig. 5B lower) .
Interestingly, a small number of tumors did develop on the null background which were further analyzed by immunohistochemistry. Unlike in the wild-type tumors, TGFβRII and IGF2BP2 expression were absent at the edge of tumor on the Hmga2 -/-genotypic background (Fig, 5B lower) . In addition, β-catenin did not relocalize to the nucleus and was detected both at the edge and throughout the , Fig. 4) . Interestingly, E-cadherin was present both throughout the tumor and at the edge of the tumor (Fig. 5B lower) . These results suggest that HMGA2 is required in mammary tumorigenesis for tumor development and progression that is initiated through the Wnt1 pathway, via the TGFβ signaling pathway. (29) . A third cell line was generated which was a derivative of the 4TO7 cell line but expressed HMGA2-GFP (4TO7-HMGA2-GFP)(see Material and Methods). As was the case for the cell line described in Figure 1B , the 4TO7 cell attained a mesenchymal phenotype upon transfection of HMGA2 exhibiting spindle cell metaplasia and loss of E-cadherin.
HMGA2 and Metastasis.
Interestingly, in our study TGFβRII was up-regulated in 4T1 cells as compared to in 4TO7 cells (Supplementary, Fig. 5 ). Mice were inoculated with three different cell lines and formed palpable primary tumors within 6 days. HMGA2 was enhanced in the primary tumors injected with the 4T1 cells (Fig. 6A) . Remarkably, 4TO7-HMGA2-GFP cells formed primary tumors more rapidly than the 4TO7-Mock cells after 9 days (Fig.   6B ) and grew at the same rate as the 4T1 cells. In the 4T1 metastatic tumors, HMGA2 expressing cells were detected at the edge of the lung tumors and liver stroma (Glisson's capsule) into the parenchyma (Supplementary Fig. 6A ).
In order to determine if the loss of Hmga2 reduced the invasive properties of the 4T1 mouse invasive breast cancer cells and subsequent tumor development, we generated 4T1 cells stably expressing Hmga2 shRNA (4T1-Hmga2-shRNA cells)(see Material and Methods). Hmga2 mRNA levels were remarkably reduced in the 4T1-Hmga2-shRNA cells (Fig. 6C ) and these 4T1-Hmga2-shRNA cells exhibited marked reduction of invasion in a matrigel invasion assay (Fig. 6D ).
Most remarkably, 7 days after injection the 4T1-Hmga2-shRNA cells formed primary tumors more slowly than the 4TO7-NTC-shRNA cells in vivo (Fig. 6E) .
Since the primary tumors were smaller no assessment of metastasis could be formulated for the 4T1-hmga2-shRNA cells.
Interestingly, metastases developed in 9 of 10 mice injected with 4TO7-HMGA2-GFP cells ( ## =P<0.0001) (Fig. 6F, Supplementary Fig. 6B ) but exclusively in the liver and no metastasis was observed in the lung. So, the 4TO7-HMGA2-GFP cells are converted to a metastatic form in their ability to invade and colonize the liver parenchyma. were not detected in the centre of the primary tumors (Fig. 6G upper) . Similarly, in the liver metastases, the majority of the 4TO7-HMGA2-GFP cells were detected especially in the liver parenchyma invaded by cancer cells emanating from the blood vessel into the stroma (Fig. 6G lower, Supplementary Fig. 7 ).
These results suggest that when HMGA2 is expressed in cells during tumor development, the cells have the ability to localize to the invasive front of the primary tumor and HMGA2 can directly induce liver metastasis in the mouse allograft model.
Discussion
The described studies define a fundamental pathway in the EMT and tumor metastasis. Our initial in vitro experiments established that HMGA2 converts noninvasive cell types into their invasive counterparts through the induction of the EMT. Importantly, the cells at the invasive front of human tumors preferentially express HMGA2 where the tumor cells exhibit the EMT and it is these cells that are said to be destined to become metastatic and progress further onto malignancy (10) . The genetic studies with the mouse model of tumorigenesis reveal that the HMGA2 pathway is essential for tumor pathogenesis for the majority of tumors. Furthermore, the molecular mechanism by which HMGA2 CAN-12-3848 mediates the induction of EMT was determined to go through the TGFβ canonical pathway, and specifically through the activation of the TGFβRII. Most decisively, the expression of TGFβRII was absent in the HMGA2 independent tumors leading to the conclusion that HMGA2 dependent tumor pathogenesis is mediated via the TGFβRII. Consistent with the distribution of the expression pattern of HMGA2 and its activation of the TGFβRII, we demonstrated that the TGFβRII is also expressed exclusively at the invasive front of human tumors.
The hypothesis for a relationship between genes that are involved in mesenchymal proliferation and differentiation and the EMT and hence invasion and metastasis is further strengthened by studies of these genes in human tumors. For HMGA2, the present study demonstrated that the protein is localized to the invasive front. Consistent with these findings, there were a number of studies that suggested a positive correlation between HMGA2 expression and severity of tumor grade for a variety of tumor cell types (5, 9) . Furthermore, the presence of HMGA2 in the blood (presumably due to metastasizing circulating tumor cells) correlates with either tumor recurrence or mortality (6). Where analyzed, there are a number of similar observations as for HMGA2 on the expression of Snail, Slug and Twist in human tumors. Both Snail and Twist are maximally expressed in multiple tumor types of the most severe grade (30, 31) and expression in breast cancer is related to patients survival (32) . Pertinently, Snail was mainly expressed at the invasive front in human oesophageal cancer (33) and both Snail and Twist are also found at the invasive front of the tumor in (34) . In addition, Slug is predominantly expressed at the invasive front of pancreatic tumor (35) . We would predict that future cellular localization studies would reveal that these genes are also expressed at the invasive front in cells that have undergone EMT. The correlative human studies in conjunction with the in vitro and in vivo studies described in the results section clearly define the functional significance of HMGA2 expression in the EMT and metastasis. Although all three of these mesenchyme-specific genes induce EMT, this does not imply that they are in the same molecular pathway.
For example, Twist does not induce Snail expression in carcinoma cells (36) and and our studies show there was not a statistically significant difference in twist or snail expression by HMGA2 in MCF7 cells (Supplementary Fig. 8 ). It should be In the present study, ectopic HMGA2 expression mediates EMT through an interaction via the TGFβ signaling pathway that has been strongly implicated in EMT induction in vitro for a number of cell types (20, 38) . Specifically, ectopic HMGA2 expression induced EMT and invasiveness through up-regulation of the TGFβRII in MCF-7 breast cancer cells (Fig. 1,3 ) without the activation of TGFβ1 expression ( Supplementary Fig. 9 ). Also, in our study, the endogenous HMGA2 expression was not increased by TGFβ1 treatment in the MCF-7 breast cancer cells ( Supplementary Fig. 10 ). It should be noted that with NMuMG cells, HMGA2 can be considered a "driver" of the EMT and metastasis and delineation of the HMGA2 pathway will potentially define a series of genes specific for invasion and metastasis of epithelial cancer cells. 
